Clinical Trial Update: Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (EnrichPSMA) is evaluating relugolix as androgen deprivation therapy to improve PSMA PET/CT imaging in high-risk or very high-risk pros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Relugolix (Relugolix)

Snippet

Sponsor: Mayo Clinic | Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Status: RECRUITING